MediGene

Cash-strapped Medigene lays off 40%, pauses plan to enter clinic

Medigene will slim its head count by 40% and pause plans to get its first asset into the clinic in order to channel cash to its T cell receptor-guided therapies.

James Waldron Nov 26, 2024 6:52am

BioNTech jumps into PRAME game, paying $29M for T-cell therapy

Feb 22, 2022 7:10am

Medigene loses CMO after slashing staff, blood cancer program

Mar 19, 2021 9:35am

Medigene shares sag as it axes TCR-T blood cancer drug

Jan 28, 2021 8:45am

Ramaswamy's latest 'vant' debuts with Medigene TCR partnership

Apr 4, 2019 11:17am

Bluebird adds targets, $500M in milestones to Medigene TCR pact

May 14, 2018 9:05am